Ryan Robinson
Direttore Finanziario/CFO presso Tourmaline Bio, Inc.
Posizioni attive di Ryan Robinson
Società | Posizione | Inizio | Fine |
---|---|---|---|
Tourmaline Bio, Inc.
Tourmaline Bio, Inc. Miscellaneous Commercial ServicesCommercial Services Part of Tourmaline Bio, Inc., Tourmaline Sub, Inc. is a late-stage clinical biotechnology company based in New York, NY. The company's lead program, Tour006, is an anti-IL-6 antibody with high binding affinity and a naturally long half-life. Tour006 has been studied in over 400 autoimmune patients across six clinical trials. Tourmaline Sub plans to develop Tour006 for thyroid eye disease (TED) and atherosclerotic cardiovascular disease (ASCVD), with additional indications being considered. The company, founded in 2021 by Sandeep Kulkarni and Caley M. Castelein, is focused on developing transformative medicines for patients with life-altering immune diseases. Sandeep Kulkarni has been the CEO since 2021. Tourmaline Sub was acquired by Talaris Therapeutics, Inc. on October 19, 2023, for $43.50 million. | Comptroller/Controller/Auditor | 01/07/2023 | - |
Direttore Finanziario/CFO | 01/07/2023 | - | |
Treasurer | 01/07/2023 | 19/10/2023 |
Storia della carriera di Ryan Robinson
Precedenti posizioni note di Ryan Robinson
Società | Posizione | Inizio | Fine |
---|---|---|---|
Korro Bio, Inc.
Korro Bio, Inc. BiotechnologyHealth Technology Korro Bio, Inc. engages in the development of a bio therapeutics. It focuses on a proprietary platform designed to selectively edit messenger RNA and recode specific codons to effect changes in protein structure and function across multiple tissues. The company was founded by Jean-Fran?ois Formela, Josh Rosenthal, Nessan Bermingham, and Andrew Fraley in 2018 and is headquartered in Cambridge, MA. | Treasurer | 01/07/2020 | 01/07/2023 |
Formazione di Ryan Robinson
Boston College | Graduate Degree |
Statistiche
Distribuzione geografica
Stati Uniti | 4 |
Posizioni
Treasurer | 3 |
Comptroller/Controller/Auditor | 2 |
Director of Finance/CFO | 2 |
Settori
Consumer Services | 2 |
Health Technology | 2 |
Commercial Services | 2 |
Posizioni ricoperte
Attive
Inattive
Società quotate in Borsa
Aziende private
Società collegate
Aziende private | 2 |
---|---|
Korro Bio, Inc.
Korro Bio, Inc. BiotechnologyHealth Technology Korro Bio, Inc. engages in the development of a bio therapeutics. It focuses on a proprietary platform designed to selectively edit messenger RNA and recode specific codons to effect changes in protein structure and function across multiple tissues. The company was founded by Jean-Fran?ois Formela, Josh Rosenthal, Nessan Bermingham, and Andrew Fraley in 2018 and is headquartered in Cambridge, MA. | Health Technology |
Tourmaline Bio, Inc.
Tourmaline Bio, Inc. Miscellaneous Commercial ServicesCommercial Services Part of Tourmaline Bio, Inc., Tourmaline Sub, Inc. is a late-stage clinical biotechnology company based in New York, NY. The company's lead program, Tour006, is an anti-IL-6 antibody with high binding affinity and a naturally long half-life. Tour006 has been studied in over 400 autoimmune patients across six clinical trials. Tourmaline Sub plans to develop Tour006 for thyroid eye disease (TED) and atherosclerotic cardiovascular disease (ASCVD), with additional indications being considered. The company, founded in 2021 by Sandeep Kulkarni and Caley M. Castelein, is focused on developing transformative medicines for patients with life-altering immune diseases. Sandeep Kulkarni has been the CEO since 2021. Tourmaline Sub was acquired by Talaris Therapeutics, Inc. on October 19, 2023, for $43.50 million. | Commercial Services |
- Borsa valori
- Insiders
- Ryan Robinson
- Esperienza